Founded in 2015, Apollo Medical Optics (AMO) develops optical imaging devices based on the revolutionary technology known as Optical Coherence Tomography (OCT). AMO’s core technology originated at National Taiwan University (NTU) when AMO’s researchers first began investigating medical optics. Our unique crystal fiber technology brings the OCT to a new era, which gives AMO’s product competitive advantage, with cellular-level resolution and faster scanning speed.
Our in vivo OCT system’s primary goal is to cover the skin health area that includes both skin cancer monitoring and detection, and aesthetic applications. AMO will extend our territories into ophthalmology, pathology, endoscopy, and research markets with our platform technology in the future. Moreover, a combination of medical imaging and artificial intelligence is also our plan. AMO will continue to advance our technology to provide the best healthcare imaging system.
2016 | The selection award of “Taiwan Industry Innovation Platform Program”, MOEA |
2016 | 2016 “Protechting-Innostar” Global Innovation Competition: 1st place |
2017 | Certification to ISO 13485:2016 |
2019 | Awarded the grant by “A+ Industrial Innovation R&D Program”, MOEA |
2020 | ApolloVue® S100 received US FDA 510(k) Clearance |
2020 | Awarded the 17th Taiwan Innovation Award |
2020 | ApolloVue® S100 awarded 2021 Taiwan Excellence Award |
2021 | ApolloVue® S100 received TFDA clearance |